Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PN-943

Other · developed by Protagonist Therapeutics

Phase 2 Most advanced trial (none active)
PTGX Developer
1 Registered trials

What is PN-943?

PN-943 is an orally administered agent studied in chronic moderate to severe ulcerative colitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Gastroenterology
Developer
Protagonist Therapeutics, Inc. (PTGX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04504383 Phase 2 Ulcerative Colitis Chronic Moderate Completed PTGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis Chronic ModerateUlcerative Colitis Chronic Severe

More from Protagonist Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PTGX page.

Follow PTGX, the company behind PN-943

See PTGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.